Overcoming challenges in the diagnosis, prevention, and treatment of pediatric drug-resistant tuberculosis

References

• Walsh J. Review on antimicrobial resistance: tackling drug-resistant infections. The Wellcome Trust. 2015, February. http://amr-review.org/.
   Google Scholar
• Graham SM, Sismanidis C, Menzies HJ, et al. Importance of tuberculosis to address child survival. Lancet. 2014;383:1605–1607.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Definitions and reporting framework for tuberculosis, 2013 revision, updated December 2014. [cited 2017 Jan 3]. Available from :http://www.who.int/tb/publications/definitions/en/
   Google Scholar
• World Health Organization. Global TB report 2016. [cited 2017 Jan 3]. Available from: http://www.who.int/tb/publications/global_report/en/
   Google Scholar
• Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet. 2014;383:1572–1579.
   PubMed Web of Science ®Google Scholar
• Becerra MC, Swaminathan S. Commentary: a targets framework: dismantling the invisibility trap for children with drug-resistant tuberculosis. J Public Health Policy. 2014 Nov;35(4):425–454.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). WHO treatment guidelines for drug resistant tuberculosis: 2016 update. WHO/HTM/TB/2016.04. Geneva: World Health Organization; 2016.
   Google Scholar
• Ahuja SD, Ashkin D, Avendano M. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. Plos Med Public Lib Sci. 2012;9(8):e1001300.
   PubMed Web of Science ®Google Scholar
• Schaaf HS, Garcia-Prats AJ, Hesseling AC, et al. Managing multidrug-resistant tuberculosis in children: review of recent developments. Curr Opin Infect Dis. 2014;27:211–219.
   PubMed Web of Science ®Google Scholar
• Chiang S, Starke J, Miller A, et al. Baseline predictors of treatment outcomes in children with multidrug-resistant tuberculosis: a retrospective cohort study. Clin Infect Dis. 2016;63:1063–1071. DOI:10.1093/cid/ciw489
   PubMed Web of Science ®Google Scholar
• Harausz EP, Garcia-Prats AJ, Schaaf HS, et al., Hesseling AC for the Pediatric Evidence Synthesis Group. Global treatment outcomes in children with paediatric MDR-TB: systematic review and meta-analysis. Presented at: The 46th Union World Conference on Lung Health; 5 December 2015; Cape Town, South Africa.
   Google Scholar
• Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med. 2012 Nov 15;186(10):953–964. PMID: 22983960.
   PubMed Web of Science ®Google Scholar
• Perez-Velez CM, Marais BJ. Tuberculosis in children. N Engl J Med. 2012 Jul 26;367(4):348–361. DOI:10.1056/NEJMra1008049
   PubMed Web of Science ®Google Scholar
• Brigden GF, Furin J, van Gulik C, et al. Getting it right for children: improving tuberculosis treatment access and new treatment options. Expert Rev Anti-Infective Ther. 2015;13(4):451–461.
   PubMed Web of Science ®Google Scholar
• Whittaker E, Zar HJ. Promising directions in the diagnosis of childhood tuberculosis. Expert Rev Respir Med. 2012;6(4):385–395.
   PubMed Web of Science ®Google Scholar
• Zar HJ, Hanslo D, Apolles P, et al. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet. 2005;365:130–134.
   PubMed Web of Science ®Google Scholar
• Scott LE, Beylis N, Nicol M, et al. The diagnostic accuracy of Xpert MTB/RIF on extra pulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa. J Clin Microbiol. 2014;52(6):1818–1823.
   PubMed Web of Science ®Google Scholar
• Doumit M, Jaffé A. Use of the Lung Flute for sputum induction in children with cystic fibrosis: a pilot study. Pediatr Pulmonol. 2015 Apr;50(4):340–343. Epub 2014 Dec 8. DOI:10.1002/ppul.23126
   PubMed Web of Science ®Google Scholar
• Atwine D, Nansumba M, Orikiriza P, et al. Intra-gastric string test: an effective tool for diagnosing tuberculosis in adults unable to produce sputum. Int J Tuberc Lung Dis. 2015 May;19(5):558–564. DOI:10.5588/ijtld.14.0810
   PubMed Web of Science ®Google Scholar
• Dunn J, Starke J, Revell P. Laboratory diagnosis of Mycobacterium tuberculosis infection and disease in children. J Clin Microbiol June. 2016;54(6):1434–1441.
   PubMed Web of Science ®Google Scholar
• Cruz A, Revell P, Starke J. Gastric aspirate yield for children with suspected pulmonary tuberculosis. J Pediatr Infect Dis. 2012. DOI:10.1093/jpids/pis089
   Google Scholar
• Nicol MP, Spiers K, Workman L, et al. Xpert MTB/RIF testing of stool samples for the diagnosis of pulmonary tuberculosis in children. Clin Infect Dis. 2013 Aug;57(3):e18–21. Epub 2013 Apr 11. DOI:10.1093/cid/cit230
   Google Scholar
• Satti H, Mclaughlin MM, Omotayo DB, et al. Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence. Plos One. 2012;7(5):e37114.
   PubMed Web of Science ®Google Scholar
• Muyoyeta M, Maduskar P, Moyo M, et al. The sensitivity and specificity of using a computer aided diagnosis program for automatically scoring chest X-rays of presumptive TB patients compared with Xpert MTB/RIF in Lusaka Zambia. Plos ONE. 2014;9(4):e93757.
   PubMed Web of Science ®Google Scholar
• Padayatchi N, Bamber S, Dawood H, et al. Multidrug-resistant tuberculous meningitis in children in Durban, South Africa. Pediatr Infect Dis J. 2006 Feb;25(2):147–150.
   PubMed Web of Science ®Google Scholar
• Amanullah F, Ashfaq M, Kowhaja S, et al. High tuberculosis prevalence in children exposed at home to drug-resistant tuberculosis. Int J Tuberculosis Lung Dis. 2014;18(5):520–527.
   PubMed Web of Science ®Google Scholar
• Furin J, Mafukidze A, Brigden G, et al. A bitter pill to swallow: the need for better medications for drug-resistant TB in children. Int J Tuberculosis Lung Dis. 2015;19(12):S55–60.
   PubMed Web of Science ®Google Scholar
• Revised National Tuberculosis Control Program. DOTS-plus guidelines. Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare, Nirman Bhavan, New Delhi – 110011; 2010 cited 2016 July 21. Available from http://health.bih.nic.in/Docs/Guidelines/Guidelines-DOTS-Plus.pdf
   Google Scholar
• Monedero I, Furin J. Programmatic management of children with drug-resistant tuberculosis: common sense and social justice. Public Health Action. 2015 Jun 21;5(2):92. PMID: 26393107; PMCID: PMC4487481.
   PubMed Web of Science ®Google Scholar
• Ettehad D, Schaaf HS, Seddon JA, et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:449–456.
   PubMed Web of Science ®Google Scholar
• Seddon JA, Hesseling AC, Godfrey-Faussett P, et al. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax. 2014;69:458–464.
   PubMed Web of Science ®Google Scholar
• Drobac PC, Mukherjee JS, Joseph JK, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics. 2006;117:2022–2029.
   PubMed Web of Science ®Google Scholar
• Seddon JA, Thee S, Jacobs K, et al. Hearing loss in children treated for multidrug-resistant tuberculosis. Journal of Infection. 2013;66:320–329.
   PubMed Web of Science ®Google Scholar
• Sentinel Project on Pediatric Drug Resistant Tuberculosis. Rapid clinical advice: the use of delamanid and bedaquiline for children with drug-resistant tuberculosis. Boston (MA): Sentinel Project. [cited 2016 July 17]. Available from: http://sentinel-project.org
   Google Scholar
• Franck C, Seddon JA, Hesseling AC, et al. Assessing the impact of multidrug-resistant tuberculosis in children: an exploratory qualitative study. BMC Infect Dis. 2014;14:ISSN: 1471-2334.
   PubMed Web of Science ®Google Scholar
• Taneja R, Garcia-Prats A, Furin J, et al. Pediatric formulations of second-line anti-tuberculosis medications: challenges and considerations. Int J Tuberculosis Lung Dis. 2015;19(12):S61-68.
   PubMed Web of Science ®Google Scholar
• Garcia-Prats A, Donald P, Hesseling A, et al. Second-line antituberculosis drugs in children: a commissioned review for the World Health Organization 19th expert committee on the selection and use of essential medicines. 2013 Jan 11 [cited 2016 May 5]. Available from: http://www.who.int/selection_medicines/committees/expert/19/applications/TB_624_C_R.pdf
   Google Scholar
• Health Advocacy Innovations. PedDTB. [cited 2016 July 17]. Available from: http://www.healthadvocacyinnovations.org/projects/
   Google Scholar
• Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16(10):1193–1201.
   PubMed Web of Science ®Google Scholar
• Shah NS, Yuen C, Heo M, et al. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systemic review and meta-analysis. Clin Infect Dis. 2014;58(3):381–391.
   PubMed Web of Science ®Google Scholar
• Sentinel Project on Pediatric Drug Resistant Tuberculosis. Management of drug-resistant tuberculosis in children: a field guide. 2nd ed.. 2014. Boston (MA): Sentinel Project. [cited 2016 June 10]. Available from http://sentinel-project.org/2014/07/22/second-edition-of-management-of-multidrug-resistant-tuberculosis-in-children-a-field-guide/
   Google Scholar
• Esposito S, D’Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J. 2014;44(3):811–815.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis. 2010;50(S3):S 184–94.
   PubMed Web of Science ®Google Scholar
• Zumla A, Schito M, Maeurer M. Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers and vaccines. Lancet Infect Dis. 2014;14(4):267–269.
   PubMed Web of Science ®Google Scholar
• Albert H, Nathavitharana R, Isaacs C, et al. Development, roll out, and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J. 2016;48:516–525. [cited 2016 July 13]. DOI:10.1183/13993003.00543-2016
   PubMed Web of Science ®Google Scholar
• Allande D, Rownecki M, Smith L, et al. Xpert MTB/RIF ultra: a new near-patient test with sensitivity equal to culture. Conference on Retroviruses and Opportunistic Infections, Abstract 91. Seattle, WA, USA. 2015 February 23-26.
   Google Scholar
• Cox HS, Furin JJ, Mitnick CD, et al. The need to accelerate access to new drugs for multidrug-resistant tuberculosis. Bull World Health Organ. 2015 Jul 1;93(7):491–497.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim guidance; 2013. Geneva: World Health Organization. ISBN 978 92 4 150548 2.
   Google Scholar
• World Health Organization. 2016. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance. Geneva: World Health Organization. cited 2017 January 3 Available from http://who.int/tb/publications/Delamanid_interim_policy/en/
   Google Scholar
• Hafkin J, Frias M, Hesseling A, et al. Pharmacokinetics and safety of delamanid in pediatric MDR-TB patients, ages 6-17 years. Poster presented at the International Conference on Antimicrobial Agents and Chemotherapy. Poster A-960. 2015 September 18-21. San Diego, CA, USA.
   Google Scholar
• Hafkin J, Frias M, De Leon A, et al. Long-term safety, tolerability, and pharmacokinetics of delamanid in pediatric MDR-TB patients ages 12-17 years. Poster presented at the 46th Union World Conference on Lung Health. Poster EP-115-04. 2015 December 2-6. Cape Town, South Africa.
   Google Scholar
• Guglielmetti L, Jaspard M, Le Dû D, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J. 2016. DOI:10.1183/13993003.01799-2016.
   PubMed Web of Science ®Google Scholar
• Nachman S, Ahmed A, Amanullah F, et al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis. 2015 Jun. cited 2016 Jan 06;15(6):711–720. PMID: 25957923; PMCID: PMC4471052
   PubMed Web of Science ®Google Scholar
• Gegia M, Jenkins HE, Kalandadze I, et al. Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009-2011. Int J Tuberc Lung Dis. 2013 May;17(5):624–629.
   PubMed Web of Science ®Google Scholar
• IMPAACT Protocols Snapshot. [ cited 2016 June 10]. Available from: http://impaactnetwork.org/DocFiles/Index/StudyStatusTbl.pdf
   Google Scholar
• Yuen CM, Tolman AW, Cohen T, et al. Isoniazid-resistant tuberculosis in children: a systematic review. Pediatr Infect Dis J. 2013 May;32(5):e217–26. DOI:10.1097/INF.0b013e3182865409
   Google Scholar
• Yuen CM, Jenkins HE, Rodriguez CA, et al. Global and regional burden of isoniazid-resistant tuberculosis. Pediatrics. 2015 Jul 1; 136: e50–9. Epub 2015 Jun 1. DOI:10.1542/peds.2015-0172
   Google Scholar
• Gegia M, Winters N, Benedetti A, et al. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2016 Nov 16; pii: S1473-3099(16)30407-8. DOI:10.1016/S1473-3099(16)30407-8
   PubMed Web of Science ®Google Scholar
• Brust JC, Shah NS, Scott M, et al. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberculosis Lung Dis. 2012;16(8):998–1004.
   PubMed Web of Science ®Google Scholar
• Weiss P, Chen W, Cook VJ, et al. Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis. BMC Infect Dis. 2014;14:333.
   PubMed Web of Science ®Google Scholar
• Ebonwu JI, Tint KS, Ihekweazu C. Low treatment initiation rates among multidrug-resistant tuberculosis patients in Gauteng, South Africa, 2011. Int J Tuberculosis Lung Dis. 2013;17(8):1043–1048.
   PubMed Web of Science ®Google Scholar
• Cox H, Ramma L, Wilkinson L, et al. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa. Trop Med Int Health. 2015;20(10):1337–1345.
   PubMed Web of Science ®Google Scholar
• Andrews JR, Stout JE. Treating multidrug-resistant tuberculosis in community settings: a wise investment. Int J Tuberculosis Lung Dis. 2015;19(2):127.
   PubMed Web of Science ®Google Scholar
• Mukherjee JS, Joseph JK, Rich ML, et al. Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from Lima, Peru. Int J Tuberc Lung Dis. 2003 Jul;7(7):637–644. PMID: 12870684.
   PubMed Web of Science ®Google Scholar
• Cox H, Hughes J, Daniels J, et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis. 2014;18(4):441–448.
   PubMed Web of Science ®Google Scholar
• Frick M, von Delft D, Kumar B. End stigmatizing language in tuberculosis research and practice. Bmj. 2015 Mar 23;350: h1479. DOI:10.1136/bmj.h1479
   Google Scholar
• Morris MD, Quezada L, Bhat P, et al. Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: a patient’s perspective. Int J Tuberculosis Lung Dis. 2013;17(7):954–960.
   PubMed Web of Science ®Google Scholar
• Albuquerque T, Isaakidis P, Das M, et al. Infection control in households of drug-resistant tuberculosis patients co-infected with HIV in Mumbai, India. Public Health Action. 2014;4(1):35–41.
   PubMedGoogle Scholar
• Nardell E, Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings. Int J Tuberculosis Lung Dis. 2010;14(10):1233–1243.
   PubMed Web of Science ®Google Scholar
• London L, Cox H, Coomans F. Multidrug-resistant TB: implementing the right to health through the right to enjoy benefits of scientific progress. Health Hum Rights J. 2016;18(1):25–41.
   PubMed Web of Science ®Google Scholar
• van Custem G, Isaakidis P, Farley J, et al. Infection control for drug-resistant tuberculosis: early diagnosis and treatment is the key. Clin Infect Dis. 2016;62(S3):S238–43.
   PubMed Web of Science ®Google Scholar
• Becerra MC, Franke MF, Appleton SC, et al. Tuberculosis in children exposed at home to multidrug-resistant tuberculosis. Pediatr Infect Dis J. 2013 Feb;32(2):115–119.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of multidrug-resistant tuberculosis; 2014. Geneva: World Health Organization. ISBN 978 92 4 154880 9.
   Google Scholar
• Mckenna L, Frick M, Seaworth B, et al. The “invisibility” of children with tuberculosis. J Public Health Policy. 2015;36:123–125.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. WHO/HTM/TB/2006.371, WHO/FCH/CAH/2006.7. Geneva, Switzerland: WHO; 2006.
   Google Scholar
• Zimri K, Hesseling A, Godfrey-Faussett P, et al. Why do child contacts of multidrug-resistant tuberculosis not come to the assessment clinic? Public Health Action. 2012;2(3):71–75.
   PubMedGoogle Scholar
• Mindachew M, Deribew A, Memiah P, et al. Perceived barriers to the implementation of isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J. 2014 cited 2014 Jan 17;17:26. DOI:10.11604/pamj.2014.17.26.2641
   PubMedGoogle Scholar
• van Wyk SS, Reid AJ, Mandalakas AM, et al. Operational challenges in managing isoniazid preventive therapy in child contacts: a high-burden setting perspective. BMC Public Health. 2011;11:544.
   PubMed Web of Science ®Google Scholar
• Seddon JA, Fred D, Amanullah F, et al. Post-exposure management of multidrug-resistant tuberculosis contacts: evidence-based recommendations. Policy brief no. 1. Dubai, United Arab Emirates: Harvard Medical School Center for Global Health Delivery–Dubai; 2015.
   Google Scholar
• Seddon J, Hesseling A, Finlayson H, et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis. 2013;57(12):1676–1684.
   PubMed Web of Science ®Google Scholar
• Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberculosis Lung Dis. 2014;18(8):912–918.
   PubMed Web of Science ®Google Scholar
• Oxlade O, Menzies D. Fluoroquinolone therapy for the prevention of multidrug-resistant tuberculosis in contacts. A cost-effectiveness analysis. Am J Respir Crit Care Med. 2015 Jul 15;192(2):229–237. DOI:10.1164/rccm.201501-0069OC
   PubMed Web of Science ®Google Scholar
• RESIST-TB. Clinical trials progress report. [cited 2016 July 17]. Available from: http://www.resisttb.org/?page_id=1602
   Google Scholar
• Center for Global Health Delivery-Dubai. Policy brief: post-exposure management of multidrug-resistant tuberculosis contacts: evidence-based recommendations. Dubai, United Arab Emirates: Harvard Medical School; 2015.
   Google Scholar
• Medicins Sans Frontiers. Out of the dark: meeting the needs of children with TB; 2012. Geneva: Medicins Sans Frontiers. Available from http://www.msfaccess.org/content/out-dark-meeting-needs-of-children-with-TB.
   Google Scholar
• Grandjean L, Gilman RH, Martin L, et al. Transmission of multidrug-resistant and drug-susceptible tuberculosis within households: a prospective cohort study. Plos Med. 2015;12(6):e1001843. DOI:10.1371/journal.pmed.1001843
   PubMed Web of Science ®Google Scholar
• Isaakidis P, Das M, Kumar AMV, et al. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India. Plos ONE. 2014;9(10):e110461. DOI:10.1371/journal.pone.0110461
   PubMed Web of Science ®Google Scholar
• Furin J, Cox H. Outbreak of multidrug-resistant tuberculosis on Daru Island. Lancet Respir Med. 2016. cited 2016 March 23. DOI:10.1016/S2213-2600(16)00101-6
   PubMed Web of Science ®Google Scholar
• Shah NS, Brust J, Mathema B, et al. Majority of XDR TB cases are due to transmission in a high-HIV-prevalence setting. Conference on Retroviruses and Opportunistic Infections, Abstract 92. February 23-26, 2015 Seattle, Washington, USA.
   Google Scholar
• Furin J, Isaakidis P. The tuberculosis emergency in Eastern Europe. Lancet HIV. 2016;3:e107-e108.
   PubMed Web of Science ®Google Scholar
• Moon S, Sridhar D, Pate M, et al. Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM independent panel on the global response to Ebola. Lancet. 2015;386(10009):2204–2221.
   PubMed Web of Science ®Google Scholar
• Seddon JA, Hesseling AC, Marais BJ, et al. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa. Int J Tuberculosis Lung Dis. 2012;16(7):928–933.
   PubMed Web of Science ®Google Scholar
• Uplekar M, Weil D, Lonnroth K, et al. WHO’s new end TB strategy. The Lancet. 2015;385:1799–1801. cited 2015 March 24. DOI:10.1016/S0140-6736(15)60570-0
   PubMed Web of Science ®Google Scholar
• Farmer P, Nardell E. Nihilism and pragmatism in tuberculosis control. Am J Public Health. 1998 Jul;88(7):1014–1015.
   PubMed Web of Science ®Google Scholar
• Yong Kim J, Shakow A, Mate K, et al. Limited good and limited vision: multidrug-resistant tuberculosis and global health policy. Soc Sci Med. 2005 Aug;61(4):847–859.
   PubMed Web of Science ®Google Scholar
• Hanekom W. Critical questions and new approaches to TB vaccinology. Presentation at TB2016. Durban: TB2016. 2016 July 16-17.
   Google Scholar